Journal
Journal of Clinical Investigation
Publication Date
7-1-2025
Volume
135
Issue
13
First Page
e189511
Document Type
Open Access Publication
DOI
10.1172/JCI189511
Rights and Permissions
Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, Harrington S, Sandoval C, Sanders B, Kuroki L, McCourt C, Hagemann AR, Thaker P, Mutch D, Powell M, Serra V, Hagemann IS, Walts AE, Karlan BY, Orsulic S, Fuh KC, Sun L, Verma P, Lomonosova E, Zhao P, Khabele D, Mullen MM. Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer. J Clin Invest. 2025 May 20;135(13):e189511. doi: 10.1172/JCI189511. : © 2025, Schab et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Recommended Citation
Schab, Angela; Compadre, Amanda; Drexler, Rebecca; Loeb, Megan; Rodriguez, Kevin; Brill, Joshua; Sandoval, Carmen; Sanders, Brooke; Kuroki, Lindsay; McCourt, Carolyn; Hagemann, Andrea R.; Thaker, Premal; Mutch, David; Powell, Matthew; Hagemann, Ian S.; Sun, Lulu; Verma, Priyanka; Lomonosova, Elena; Khabele, Dineo; Mullen, Mary M.; and et al., "Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer." Journal of Clinical Investigation. 135, 13. e189511 (2025).
https://digitalcommons.wustl.edu/oa_4/5425
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
